Archived research. Equity forecasting is part of the Runchey Research archive (methodology era 1) and is no longer actively updated. Everything remains published at its original URL. Browse the archive
Back to Forecasting
GH Forecast Markets
Guardant Health Inc.
7
Active Markets
50%
Avg Probability
All Markets
7 markets
Will Shield blood test volume reach 210,000+ tests in FY2026?
48%
Likely No
94% agreement
Feb 28, 2027
IG: 0.80
Will Shield receive ACS guideline inclusion by year-end 2026?
45%
Likely No
92% agreement
Jan 15, 2027
IG: 0.80
Will GH total revenue exceed $900M in FY2026?
55%
Likely Yes
94% agreement
Feb 28, 2027
IG: 0.64
Will GH core oncology business generate positive FCF in FY2026?
58%
Likely Yes
96% agreement
Feb 28, 2027
IG: 0.64
Will Guardant360 ADLT FDA submission occur by year-end 2026?
60%
Likely Yes
94% agreement
Jan 15, 2027
IG: 0.48
Will GH total company cash burn be below $200M in FY2026?
42%
Likely No
94% agreement
Feb 28, 2027
IG: 0.48
Will Quest co-promotion contribute materially to Shield volumes by H2 2026?
40%
Likely No
92% agreement
Jan 15, 2027
IG: 0.48
Resolution Timeline
Jan 15, 2027
Will Quest co-promotion contribute materially to Shield volumes by H2 2026?Prediction: 40%